Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference

Rhea-AI Summary

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced participation in the 35th Annual Roth Conference scheduled for March 12-14, 2023, in Dana Point, California. Citius Chairman and CEO Leonard Mazur will conduct one-on-one meetings with institutional investors on March 13th and March 14th. The conference will take place at The Ritz Carlton, Laguna Niguel. Interested investors can register through the conference website. Citius specializes in critical care products, with ongoing trials for Mino-Lok® and I/ONTAK, both under FDA review.

CRANFORD, N.J., March 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California. Citius Chairman and CEO Leonard Mazur will host one-on-one meetings with institutional investors and analysts on Monday, March 13th and Tuesday, March 14th.

Citius Chairman and CEO Leonard Mazur to host 1x1 meetings with institutional investors and analysts.

Conference Details: 

Location:	The Ritz Carlton, Laguna Niguel in Dana Point, California.
Registration:	Available on the conference website.
1x1 meetings:	Registered investors may request an in-person meeting by contacting a Roth representative at 800.678.9147 or Citius Investor Relations.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in CTCL, for which a BLA is under review by the FDA.  Mino-Lok® was granted Fast Track designation by the FDA. I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

Investor Contact:
Ilanit Allen
ir@citiuspharma.com 
908-967-6677 x113

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-the-35th-annual-roth-conference-301764734.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When is Citius Pharmaceuticals participating in the Roth Conference?

Citius Pharmaceuticals will participate in the Roth Conference from March 12-14, 2023.

Who is hosting the 1x1 meetings for Citius Pharmaceuticals at the Roth Conference?

Citius Chairman and CEO Leonard Mazur will host the 1x1 meetings.

Where is the Roth Conference being held?

The Roth Conference is being held at The Ritz Carlton, Laguna Niguel in Dana Point, California.

How can investors register for the Roth Conference?

Investors can register for the Roth Conference on the conference website.

What product candidates is Citius Pharmaceuticals currently developing?

Citius is developing Mino-Lok® and I/ONTAK, both of which are in late-stage trials.